Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

SUMMARY: Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given d...

Descripción completa

Detalles Bibliográficos
Autores principales: McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249191/
https://www.ncbi.nlm.nih.gov/pubmed/21947137
http://dx.doi.org/10.1007/s00198-011-1791-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249191/
https://www.ncbi.nlm.nih.gov/pubmed/21947137
http://dx.doi.org/10.1007/s00198-011-1791-y

Ejemplares similares